Brain Mitochondrial Bioenergetics in Genetic Neurodevelopmental Disorders: Focus on Down, Rett and Fragile X Syndromes

Abstract

Mitochondria, far beyond their prominent role as cellular powerhouses, are complex cellular organelles active as central metabolic hubs that are capable of integrating and controlling several signaling pathways essential for neurological processes, including neurogenesis and neuroplasticity. On the other hand, mitochondria are themselves regulated from a series of signaling proteins to achieve the best efficiency in producing energy, in establishing a network and in performing their own de novo synthesis or clearance. Dysfunctions in signaling processes that control mitochondrial biogenesis, dynamics and bioenergetics are increasingly associated with impairment in brain development and involved in a wide variety of neurodevelopmental disorders. Here, we review recent evidence proving the emerging role of mitochondria as master regulators of brain bioenergetics, highlighting their control skills in brain neurodevelopment and cognition. We analyze, from a mechanistic point of view, mitochondrial bioenergetic dysfunction as causally interrelated to the origins of typical genetic intellectual disability-related neurodevelopmental disorders, such as Down, Rett and Fragile X syndromes. Finally, we discuss whether mitochondria can become therapeutic targets to improve brain development and function from a holistic perspective.

PGC-1α integrates insulin signaling with mitochondrial physiology and behavior in a Drosophila model of Fragile X Syndrome

“…Notably, diminished PGC-1α expression has been reported in other syndromic forms of intellectual disability (ID) and autism, including Down Syndrome and Rett Syndrome 43 , 59 . The convergence of multiple distinct genetic forms of ID and autism on decreased PGC-1α expression suggests shared mechanistic underpinnings.…”

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest

“…It is the first-ever treatment to treat Rett syndrome, which is a rare, genetic neurodevelopmental disorder [50]. Rett syndrome was initially described by Andreas Rett in 1966 [52] and is characterized by a loss of verbal communication with limited nonverbal skills, loss of fine and gross motor function (including purposeful hand use), behavioral issues, seizures, hand stereotypies, and gastrointestinal problems [53][54][55]. It is the first-ever treatment to treat Rett syndrome, which is a rare, genetic neurodevelopmental disorder [50].…”

Biomaterials targeting the microenvironment for spinal cord injury repair: progression and perspectives

“…As a negatively charged polysaccharide, alginate poses a restriction on the attachment and viability of various cells. To overcome this constraint, the introduction of cations facilitates formation of hydrogels through the establishment of ionic bonds ( Valenti and Vacca, 2023 ). Various divalent cations have been investigated in the context of tissue engineering when combined with alginate hydrogels.…”